Company news
Neuren Pharmaceuticals Limited (ASX:NEU) news
Neuren Pharmaceuticals Limited news releases on 6ix. Latest, Feb 18, 2019: NNZ-2591 positive effects in Phelan-McDermid syndrome model
Press releases — page 4
NNZ-2591 positive effects in Phelan-McDermid syndrome model
February 17, 2019
Trofinetide ex-North America exclusive negotiation period
October 25, 2018
Neuren and Lanstead agree to pause settlements for 120 days
August 29, 2018
Neuren receives initial payment of US$10 million from ACADIA
August 22, 2018
Neuren and ACADIA announce agreement for North America
August 6, 2018
Announcement of buy-back - Appendix 3C
May 30, 2018
Neuren announces investment and exclusive negotiation period
May 20, 2018
First patent in Japan granted for Neurens trofinetide
April 29, 2018
Disclosure under Listing Rule 4.3D
March 29, 2018
S&P DJ Indices Announces March Quarterly Rebalance
March 8, 2018
Preliminary Final Report
February 28, 2018
Neuren announces new US patent to be granted for NNZ-2591
December 5, 2017
Consolidation/Split - NEU
November 16, 2017
Neuren FDA meeting confirms Phase 3 plan for Rett syndrome
October 12, 2017
Presentations and publication for Rett syndrome trials
October 4, 2017
Neuren Pharmaceuticals : Change of Director's Interest Notice
August 29, 2017
Neuren Pharmaceuticals : Notice under section 708A(5)(e) of the Corporations Act
August 29, 2017
Neuren Pharmaceuticals : Results of Meeting
August 28, 2017
Neuren Pharmaceuticals : reports 2017 half-year results
August 24, 2017
Neuren Pharmaceuticals : Notice of special meeting of shareholders
August 14, 2017
Neuren granted Type B Meeting with FDA for Rett syndrome
July 20, 2017
Neuren Pharmaceuticals : granted Type B Meeting with FDA for Rett syndrome
July 19, 2017
Neuren Pharmaceuticals : Appendix 3B
July 18, 2017
Neuren secures funding for key activities for Rett syndrome
June 29, 2017
Response to ASX Price Query
June 28, 2017
Neuren Pharmaceuticals : Response to ASX Price Query
June 27, 2017
Neuren Pharmaceuticals : Trading Halt
June 27, 2017
Neuren Pharmaceuticals : Investor presentation, 2 June 2017
June 1, 2017
Neuren announces grant of two new patents to 2032
May 31, 2017
Neuren Pharmaceuticals : Notice of Annual General Meeting/Proxy Form
May 29, 2017
Response to Appendix 4C Query
May 8, 2017
Neuren receives $1 million R&D Tax Incentive
April 4, 2017
Trofinetide significant clinical benefit in Rett syndrome
March 21, 2017
Neuren completes Phase 2 trial in pediatric Rett syndrome
January 29, 2017
Notice of special meeting of shareholders
November 13, 2016
Neuren receives $0.9m from exercise of last expiring options
October 27, 2016
Neuren expands Phase 2 Rett syndrome pediatric trial
August 24, 2016
Neuren presents at Rettsyndrome.org 2016 Research Symposium
June 24, 2016
Grant of new patent for Autism Spectrum Disorders
June 22, 2016
Results of Phase 2 trial in moderate to severe TBI
April 25, 2016
First subject commences Neurens Rett syndrome Phase 2 trial
April 7, 2016
Neuren awarded Rett Syndrome trial grant
March 30, 2016
Appendix 4E and Financial Report 31 December 2015
February 24, 2016
Trofinetide successful in Phase 2 trial in Fragile X
February 11, 2016
Grant of composition patent in Europe for Neurens NNZ-2591
February 10, 2016